MindWalk Cuts Antibody-Antigen Inference Time 5x with AMD-Vultr Cloud Deployment — MindWalk Holdings Corp.

Event summary

MindWalk deployed OpenFold3 on AMD Instinct MI325X GPUs via Vultr Kubernetes Engine, reducing antibody-antigen inference time by ~5x.
The deployment supports protein, RNA, DNA, ligand, and antibody-antigen prediction workflows under MindWalk's governance.
AMD Inference Microservices enabled production-grade deployment in minutes, not weeks.
The validation expands compute capacity for ReefIQ™, MindWalk's biological context layer launched in June 2026.

The big picture

MindWalk's deployment demonstrates how open-source AI models are standardizing biomolecular structure prediction, removing infrastructure barriers for pharmaceutical R&D. The validation underscores how cloud-native GPU infrastructure can reduce deployment friction while maintaining governance for regulated workflows. This shift could accelerate enterprise adoption of AI-driven drug discovery platforms.

What we're watching

Deployment Speed: Whether AMD and Vultr can sustain sub-hour deployment times for other open-source models in regulated environments.
Cost Scaling: How MindWalk's cost-per-partner metric evolves as enterprise adoption of ReefIQ accelerates.
Model Agnosticism: The pace at which pharmaceutical partners adopt MindWalk's standardized path for third-party models.